JNJ Johnson & Johnson
Company Analysis
Latest News
Johnson & Johnson's Oral Psoriasis Drug 'Icotyde' Recommended for EU Approval
A key committee of the European Medicines Agency (EMA) recommended marketing authorization for Johnson & Johnson's new drug, Icotyde. The Committee for...
Johnson & Johnson Myeloma Combo Cuts Progression Risk 89% in Phase 3
Johnson & Johnson reported positive topline results from the Phase 3 MonumenTAL-6 study for multiple myeloma. The trial evaluated a dual-antigen regimen...
Judge Casts Doubt on Evidence in 69,000 J&J Talc Lawsuits
A U.S. federal judge has raised significant doubts about the scientific evidence underpinning approximately 69,000 lawsuits alleging Johnson & Johnson's talc...
J&J Wins FDA Clearance for OTTAVA, Entering Competitive Surgical Robotics Market
Johnson & Johnson received U.S. Food and Drug Administration (FDA) De Novo authorization for its OTTAVA Robotic Surgical System. The system performs various...
Johnson & Johnson's second quarter 2026 revenue of $25.3B beats estimates as the company raises its full-year outlook.
Johnson & Johnson reported second quarter 2026 revenue of $25.31 billion, up 6.6% year-over-year, and adjusted EPS of $2.90, an increase of 4.7%. The results...
Johnson & Johnson Q2 2026 Earnings Preview: What Analysts Expect on July 15, 2026
For the second quarter of 2026, analysts expect Johnson & Johnson to report consensus revenue of $25.18 billion and adjusted EPS of $2.85, with the stock...
Johnson & Johnson's $45 Million Talc Verdict Upheld by Illinois Appellate Court
The Illinois Appellate Court upheld a $45 million verdict against Johnson & Johnson and its consumer-health spinoff, Kenvue. An original jury found that...
J&J Secures FDA Approval for Dual-Energy Cardiac Ablation Platform
Johnson & Johnson secured FDA approval for its Dual Energy THERMOCOOL SMARTTOUCH SF Platform. The system allows electrophysiologists to toggle between...
🟢 JNJ is trading 3.5% up today, driven by positive clinical trial results and a significant investment
• Shares are currently trading at $268.46, up 3.5%, rebounding sharply from the prior session’s decline. • Johnson & Johnson highlighted positive primary...
Johnson & Johnson Talc Lawsuit Ends in Mistrial as Jury Deadlocks
A Johnson & Johnson lawsuit in Los Angeles Superior Court ended in a mistrial after the jury failed to reach a unanimous verdict. Brad Yandell brought the...
🟢 JNJ soars 3.6% on positive EU drug recommendation and healthcare sector rotation
JNJ is trading 3.6% up at $253.75 today, driven by a positive recommendation from the European Medicines Agency (EMA) for an indication extension of its drug...
J&J Rejects Obesity Drug Market, Aiming for 2030 Cancer Leadership
CEO Joaquin Duato announced Johnson & Johnson will not develop GLP-1 drugs for the obesity market. The company will instead focus on sectors where it maintains...
Johnson & Johnson invests $1B in Florida, scaling ACUVUE production
Johnson & Johnson is investing over $1 billion to expand its vision care manufacturing and distribution operations in Jacksonville, Florida. The project will...
Johnson & Johnson Myeloma Combo Shows 89% Survival in Phase 3
Johnson & Johnson reported positive Phase 3 MonumenTAL-3 results for a combination therapy treating relapsed or refractory multiple myeloma. The study...
J&J eyes first-ever rare blood treatment approval after positive Imaavy data
Johnson & Johnson presented Phase 2/3 ENERGY study results for Imaavy (nipocalimab) at the European Hematology Association 2026 Congress. The therapy targets...
J&J Signals Faster Growth, Led by 4,500 New ICOTYDE Drug Prescribers
Johnson & Johnson executive Tom Cavanaugh provided a data-rich update at the Goldman Sachs Global Healthcare Conference on June 9. He signaled that the...
Johnson & Johnson buys Firefly Bio for $1B, targeting difficult tumors
Johnson & Johnson will acquire biotechnology firm Firefly Bio for $1 billion in cash. The deal integrates Firefly’s degrader antibody conjugate (DAC) platform...
Johnson & Johnson Reports 71% Myeloma Risk Reduction at ASCO 2026
Johnson & Johnson presented clinical trial results for its oncology portfolio at the 2026 American Society of Clinical Oncology (ASCO) meeting. The Phase 3...
Johnson & Johnson Wins California Talc Trial, Defeating Ovarian Cancer Claims
A Los Angeles jury cleared Johnson & Johnson of negligence on June 5, 2026. The verdict rejected claims that the company’s talc-based powders caused fatal...
🟢 Johnson & Johnson is trading 3.1% up today on defensive rotation as broader market slides
Johnson & Johnson is trading 3.1% up at $235.13 as investors rotate into defensive healthcare stocks amid a broader market decline. • The gain comes despite...